Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
5.42 EUR
345.90 M EUR
3.40 B EUR
34.55 M
About Ipsen SA
Sector
Industry
CEO
David G. Loew
Website
Headquarters
Boulogne-Billancourt
Founded
1998
ISIN
FR0010259150
FIGI
BBG000FTXNL9
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Ipsen SA stocks are traded under the ticker I7G.
We've gathered analysts' opinions on Ipsen SA future price: according to them, I7G price has a max estimate of 155.00 EUR and a min estimate of 105.00 EUR. Watch I7G chart and read a more detailed Ipsen SA stock forecast: see what analysts think of Ipsen SA and suggest that you do with its stocks.
Yes, you can track Ipsen SA financials in yearly and quarterly reports right on TradingView.
Ipsen SA is going to release the next earnings report on Feb 5, 2026. Keep track of upcoming events with our Earnings Calendar.
I7G net income for the last half-year is 334.00 M EUR, while the previous report showed 113.90 M EUR of net income which accounts for 193.24% change. Track more Ipsen SA financial stats to get the full picture.
Yes, I7G dividends are paid annually. The last dividend per share was 1.40 EUR. As of today, Dividend Yield (TTM)% is 1.20%. Tracking Ipsen SA dividends might help you take more informed decisions.
Ipsen SA dividend yield was 1.26% in 2024, and payout ratio reached 33.50%. The year before the numbers were 1.11% and 15.40% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 2, 2025, the company has 5.36 K employees. See our rating of the largest employees — is Ipsen SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ipsen SA EBITDA is 1.59 B EUR, and current EBITDA margin is 30.47%. See more stats in Ipsen SA financial statements.
Like other stocks, I7G shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ipsen SA stock right from TradingView charts — choose your broker and connect to your account.